vs
Amphastar Pharmaceuticals, Inc.（AMPH）とKADANT INC（KAI）の財務データ比較。上の社名をクリックして会社を切り替えられます
KADANT INCの直近四半期売上が大きい（$271.6M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.5倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 10.2%、差は3.1%）。KADANT INCの前年同期比売上増加率が高い（-0.0% vs -1.8%）。KADANT INCの直近四半期フリーキャッシュフローが多い（$44.1M vs $24.6M）。過去8四半期でKADANT INCの売上複合成長率が高い（6.7% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
Kadant Inc.は1991年に設立され、当初はThermo Electronの子会社として一部が私有、一部が公開取引されていたが、2001年に完全分離し現在の社名に変更した。製紙、古紙リサイクル、木材加工、荷役などの産業向けにサービスを提供し、アジア、ヨーロッパ、北米、南米に事業を展開する多国籍企業である。
AMPH vs KAI — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $271.6M |
| 純利益 | $24.4M | $27.7M |
| 粗利率 | 46.8% | 45.2% |
| 営業利益率 | 19.4% | 15.7% |
| 純利益率 | 13.3% | 10.2% |
| 売上前年比 | -1.8% | -0.0% |
| 純利益前年比 | -35.7% | -12.2% |
| EPS（希薄化後） | $0.51 | $2.35 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | — | ||
| Q3 25 | $191.8M | $271.6M | ||
| Q2 25 | $174.4M | $255.3M | ||
| Q1 25 | $170.5M | $239.2M | ||
| Q4 24 | $186.5M | $258.0M | ||
| Q3 24 | $191.2M | $271.6M | ||
| Q2 24 | $182.4M | $274.8M | ||
| Q1 24 | $171.8M | $249.0M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $27.7M | ||
| Q2 25 | $31.0M | $26.2M | ||
| Q1 25 | $25.3M | $24.1M | ||
| Q4 24 | $38.0M | $24.0M | ||
| Q3 24 | $40.4M | $31.6M | ||
| Q2 24 | $37.9M | $31.3M | ||
| Q1 24 | $43.2M | $24.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | 45.2% | ||
| Q2 25 | 49.6% | 45.9% | ||
| Q1 25 | 50.0% | 46.1% | ||
| Q4 24 | 46.5% | 43.4% | ||
| Q3 24 | 53.3% | 44.7% | ||
| Q2 24 | 52.2% | 44.4% | ||
| Q1 24 | 52.4% | 44.6% |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | 15.7% | ||
| Q2 25 | 24.2% | 15.4% | ||
| Q1 25 | 21.9% | 14.9% | ||
| Q4 24 | 24.2% | 14.3% | ||
| Q3 24 | 29.8% | 18.0% | ||
| Q2 24 | 30.3% | 17.6% | ||
| Q1 24 | 27.9% | 14.8% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 10.2% | ||
| Q2 25 | 17.8% | 10.2% | ||
| Q1 25 | 14.8% | 10.1% | ||
| Q4 24 | 20.4% | 9.3% | ||
| Q3 24 | 21.1% | 11.6% | ||
| Q2 24 | 20.8% | 11.4% | ||
| Q1 24 | 25.1% | 9.9% |
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | $2.35 | ||
| Q2 25 | $0.64 | $2.22 | ||
| Q1 25 | $0.51 | $2.04 | ||
| Q4 24 | $0.74 | $2.04 | ||
| Q3 24 | $0.78 | $2.68 | ||
| Q2 24 | $0.73 | $2.66 | ||
| Q1 24 | $0.81 | $2.10 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $124.5M |
| 総負債低いほど良い | $608.7M | $254.6M |
| 株主資本純資産 | $788.8M | $949.8M |
| 総資産 | $1.6B | $1.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.27× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | $124.5M | ||
| Q2 25 | $231.8M | $95.3M | ||
| Q1 25 | $236.9M | $91.7M | ||
| Q4 24 | $221.6M | $94.7M | ||
| Q3 24 | $250.5M | $88.4M | ||
| Q2 24 | $217.8M | $73.8M | ||
| Q1 24 | $289.6M | $81.4M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | $254.6M | ||
| Q2 25 | $607.7M | $245.7M | ||
| Q1 25 | $603.9M | $273.5M | ||
| Q4 24 | $601.6M | $285.2M | ||
| Q3 24 | $596.4M | $323.2M | ||
| Q2 24 | $586.9M | $342.0M | ||
| Q1 24 | $594.0M | $306.8M |
| Q4 25 | $788.8M | — | ||
| Q3 25 | $776.7M | $949.8M | ||
| Q2 25 | $757.5M | $926.0M | ||
| Q1 25 | $751.3M | $876.0M | ||
| Q4 24 | $732.3M | $847.1M | ||
| Q3 24 | $727.7M | $851.7M | ||
| Q2 24 | $713.3M | $807.7M | ||
| Q1 24 | $672.4M | $782.7M |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.7B | $1.5B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $1.6B | $1.4B | ||
| Q4 24 | $1.6B | $1.4B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.6B | $1.4B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | 0.27× | ||
| Q2 25 | 0.80× | 0.27× | ||
| Q1 25 | 0.80× | 0.31× | ||
| Q4 24 | 0.82× | 0.34× | ||
| Q3 24 | 0.82× | 0.38× | ||
| Q2 24 | 0.82× | 0.42× | ||
| Q1 24 | 0.88× | 0.39× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $47.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $44.1M |
| FCFマージンFCF / 売上 | 13.4% | 16.2% |
| 設備投資強度設備投資 / 売上 | 4.5% | 1.2% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 1.70× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $145.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | — | ||
| Q3 25 | $52.6M | $47.3M | ||
| Q2 25 | $35.6M | $40.5M | ||
| Q1 25 | $35.1M | $22.8M | ||
| Q4 24 | $29.0M | $51.9M | ||
| Q3 24 | $60.0M | $52.5M | ||
| Q2 24 | $69.1M | $28.1M | ||
| Q1 24 | $55.3M | $22.8M |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | $44.1M | ||
| Q2 25 | $25.0M | $36.5M | ||
| Q1 25 | $24.4M | $19.0M | ||
| Q4 24 | $16.6M | $46.3M | ||
| Q3 24 | $46.2M | $48.3M | ||
| Q2 24 | $63.1M | $23.1M | ||
| Q1 24 | $46.5M | $16.6M |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | 16.2% | ||
| Q2 25 | 14.3% | 14.3% | ||
| Q1 25 | 14.3% | 7.9% | ||
| Q4 24 | 8.9% | 17.9% | ||
| Q3 24 | 24.1% | 17.8% | ||
| Q2 24 | 34.6% | 8.4% | ||
| Q1 24 | 27.1% | 6.7% |
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | 1.2% | ||
| Q2 25 | 6.1% | 1.6% | ||
| Q1 25 | 6.3% | 1.6% | ||
| Q4 24 | 6.7% | 2.2% | ||
| Q3 24 | 7.2% | 1.5% | ||
| Q2 24 | 3.3% | 1.8% | ||
| Q1 24 | 5.1% | 2.5% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 1.70× | ||
| Q2 25 | 1.15× | 1.55× | ||
| Q1 25 | 1.39× | 0.95× | ||
| Q4 24 | 0.76× | 2.16× | ||
| Q3 24 | 1.48× | 1.66× | ||
| Q2 24 | 1.82× | 0.90× | ||
| Q1 24 | 1.28× | 0.92× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
KAI
| Flow Control | $94.8M | 35% |
| Capital | $83.2M | 31% |
| Material Handling Systems | $70.3M | 26% |
| Transferred Over Time | $17.1M | 6% |
| Other | $6.1M | 2% |
